Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Amber Heard's First Sit-Down Interview Coming This Week: Here's When And How To Watch

After losing the defamation trial ex-husband Johnny Depp brought against her, Amber Heard is set to share her thoughts on the case publicly in her first televised interview. Here are the details.

Benzinga

Barrington Hikes ICF Price Target By ~3%

Barrington analyst Kevin Steinke raised the price target on ICF International Inc (NASDAQ:ICFI) to $121 from $118 while maintaining the Outperform rating on the shares. The analyst raised the price target after reviewing the recent Q1 results and 2022 guidance reiteration. Steinke mentions that ICF recently held an Investor Day event focused on five key…

Benzinga

10 Information Technology Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $8,400 Today

Alphabet (NASDAQ:GOOGL) has outperformed the market over the past 15 years by 9.0% on an annualized basis producing an average annual return of 15.23%. Currently, Alphabet has a market capitalization of $1.42 trillion.

Benzinga

Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market capitalization of $74.42 billion.

Benzinga

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.

Benzinga

To Infinity And Not Saudi Arabia: 'Lightyear' Banned In Country Over Same-Sex Kiss

Highly anticipated movie “Lightyear” will not be released in two international territories. Here’s why the latest movie in the Toy Story franchise won’t be included there.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Lululemon Athletica Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Lululemon Athletica (NASDAQ:LULU). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

15 Analysts Have This to Say About SVB Finl Gr

SVB Finl Gr (NASDAQ:SIVB) has observed the following analyst ratings within the last quarter:

Benzinga

Where Covetrus Stands With Analysts

Within the last quarter, Covetrus (NASDAQ:CVET) has observed the following analyst ratings:

Benzinga

Why Shares Of CrowdStrike Are Trading Lower

CrowdStrike Holdings, Inc. (NASDAQ: CRWD) shares are trading lower Monday alongside several companies in the broader technology sector amid overall weakness as stocks continue to sell off following worse-than-expected May CPI data.

Benzinga

Analyst Ratings for Array Technologies

Within the last quarter, Array Technologies (NASDAQ:ARRY) has observed the following analyst ratings:

Benzinga

Jefferies Maintains Buy Rating for SVB Finl Gr: Here's What You Need To Know

Jefferies has decided to maintain its Buy rating of SVB Finl Gr (NASDAQ:SIVB) and lower its price target from $692.00 to $534.00. Shares of SVB Finl Gr are trading down 7.14% over the last 24 hours, at $411.27 per share. A move to $534.00 would account for a 29.84% increase…

Benzinga

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know

SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32% over the last 24 hours, at $44.07 per share.

Benzinga

Morgan Stanley Maintains Equal-Weight Rating for Shoals Technologies Gr: Here's What You Need To Know

Morgan Stanley has decided to maintain its Equal-Weight rating of Shoals Technologies Gr (NASDAQ:SHLS) and lower its price target from $25.00 to $21.00. Shares of Shoals Technologies Gr are trading down 6.49% over the last 24 hours, at $16.87 per share.

Benzinga

Benchmark Maintains Buy Rating for Cross Country Healthcare: Here's What You Need To Know

Benchmark has decided to maintain its Buy rating of Cross Country Healthcare (NASDAQ:CCRN) and lower its price target from $42.00 to $37.00. Shares of Cross Country Healthcare are trading down 6.22% over the last 24 hours, at $17.33 per share.

Benzinga

NTRB: Revenue Growth & New Bookings Support Positive Outlook

By M. Marin NTRB:NASDAQ READ THE FULL NTRB RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Mid-Day Market Update: Nasdaq Dips Over 400 Points; Day One Biopharmaceuticals Shares Jump

U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling by more than 400 points on Monday.

Benzinga

Here's Why This Analyst Thinks That Glimpse Group Did A Nice Job

EF Hutton analyst Ben Piggott had a chance to catch up with The Glimpse Group, Inc (NASDAQ: VRAR) management following its recent announcement of two significant acquisitions: Brightline and PulpoAR.

Benzinga

BZ Chart Of The Day: Is The Microsoft Selloff About To End?

They say that markets have memories. If it’s true, there’s a chance the selloff in Microsoft Corporation (NASDAQ: MSFT) may be about to end or at lease pause.

Benzinga

Citi Reiterated Neutral Rating On Intel, AMD - Read Why

Citi analysts Christopher Danely and Kelsey Chia observed that May notebook shipments were up 22% month on month, below Citi's expectation of up 29% due to demand deceleration. This is the fifth consecutive month where notebook shipments were below expectations.

Benzinga

70 Stocks Moving In Monday's Mid-Day Session

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.

Benzinga

374Water Soon To Begin Trading On Nasdaq

374Water Inc. (OTC:SCWO) common stock has been approved for listing on The Nasdaq Capital Market. Trading will begin at the market open on June 14, 2022, under the symbol "SCWO." "374Water's Nasdaq listing will build long-term shareholder value through increased visibility and improved trading liquidity, while addressing the growing demand for sustainable water…

Benzinga

Here's What Bitcoin's Crash Could Mean For Tesla

Electric vehicle giant Tesla Inc (NASDAQ: TSLA) purchased Bitcoin (CRYPTO: BTC) for the first time in February 2021.

1 … 402 403 404 405

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.